Drug intelligence / Profile preview

DICE-006

Development stage: Preclinical
Lead developer: DICE Therapeutics
Modality: Peptides
Administration: Oral

Overview

DICE-006 is an oral peptide agonist targeting the Interleukin-2 (IL-2) receptor, developed by DICE Therapeutics. It is being investigated as a potential therapy for autoimmune diseases. Eli Lilly acquired DICE Therapeutics in July 2023, integrating DICE-006 into its immunology and inflammation pipeline.

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on DICE-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DICE-006.

Explore the full profile